Enanta Pharmaceuticals (ENTA) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENTA shares.
View ENTA analyst ratings or view top-rated stocks.

8 brokerages have issued 1-year price objectives for Enanta Pharmaceuticals' stock. Their ENTA share price forecasts range from $33.00 to $87.00. On average, they predict the company's share price to reach $56.75 in the next year. This suggests a possible upside of 129.3% from the stock's current price.
View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts.

Enanta Pharmaceuticals' stock was trading at $46.52 on January 1st, 2023. Since then, ENTA stock has decreased by 46.8% and is now trading at $24.75.
View the best growth stocks for 2023 here.

Enanta Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 667,800 shares, a decline of 6.4% from the April 30th total of 713,500 shares. Based on an average trading volume of 198,800 shares, the short-interest ratio is currently 3.4 days. Approximately 3.5% of the shares of the stock are sold short.
View Enanta Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ENTA earnings forecast.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its earnings results on Monday, May, 8th. The biotechnology company reported ($1.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.91) by $0.12. The biotechnology company had revenue of $17.80 million for the quarter, compared to analyst estimates of $19.06 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 40.56% and a negative net margin of 153.61%. The company's revenue for the quarter was down 4.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.63) earnings per share.

ETFs with the largest weight of Enanta Pharmaceuticals (NASDAQ:ENTA) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), ETFMG Treatments Testing and Advancements ETF (GERM), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC).

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (18.08%), Armistice Capital LLC (9.56%), State Street Corp (5.70%), Braidwell LP (4.93%), Krensavage Asset Management LLC (2.87%) and Dimensional Fund Advisors LP (2.58%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or.
View institutional ownership trends.

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENTA stock can currently be purchased for approximately $24.75.

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $521.24 million and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($5.98) on an earnings per share basis.

The company employs 155 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530.